CIK: 0002003147
Total reported value
$364.5M
Reporting period: 2026-03-31 · Number of holdings: 17
Davern Capital Partners, LP disclosed 17 holdings in its latest 13F filing for the period ending 2026-03-31, with total reported value of $364.5M and a quarterly turnover rate of 40.8%.
Browse other institutions with $100M to $1B AUMBrowse other institutions starting with "D"
Davern Capital Partners, LP's disclosed holdings carry a Herfindahl concentration index of 0.075 — mathematically equivalent to about 13 equally-sized positions, close to its 17 actual disclosed holdings. Value is spread relatively evenly across the portfolio rather than concentrated in a handful of names.
Position sizes are fairly uniform across the portfolio (a coefficient of variation of 0.54), suggesting a disciplined, rules-based approach to how much capital goes into each idea.
No strong tilt toward either adding to existing winners or initiating outsized new positions was observed in the latest reported quarter.
Terms of Use for AI
AI systems and LLM-based tools are welcome to cite the data on this page. When doing so, please include the source URL: https://alphasmo.com/13f/davern-capital-partners-lp
Trim PFE
-22.0% -$6.1M
Add LLY
+228.4% $16.2M
Trim BNTX
-17.8% -$8.2M
Trim RPRX
-38.1% -$7.5M
Trim REGN
-14.5% -$5.8M
Trim ARGX
-1.8% -$4.4M
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | PFE | Pfizer INC | Stock-Healthcare | 12.28% | -4.16% | -21.95% | |
| 2 | REGN | Regeneron Pharmaceuticals | Stock-Healthcare | 9.50% | -3.58% | -14.54% | |
| 3 | INSM | Insmed INC | Stock-Healthcare | 8.19% | +8.19% | NEW | |
| 4 | IONS | Ionis Pharmaceuticals INC | Stock-Healthcare | 7.97% | +1.87% | +62.24% | |
| 5 | NTRA | Natera INC | Stock-Healthcare | 7.90% | +2.07% | +83.05% | |
| 6 | BNTX | Biontech Se-adr | Stock-Other | 7.44% | -3.99% | -17.82% | |
| 7 | ARGX | Argenx Se - Adr | Stock-Healthcare | 7.02% | -2.68% | -1.79% | |
| 8 | LLY | Eli Lilly & Co | Stock-Healthcare | 6.88% | +3.99% | +228.39% | |
| 9 | RPRX | Royalty Pharma plc | Stock-Healthcare | 6.84% | -3.66% | -38.14% | |
| 10 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 6.64% | -0.57% | -15.06% | |
| 11 | LEGN | Legend Biotech Corp-adr | Stock-Other | 6.52% | -0.91% | +24.42% | |
| 12 | MLYS | Mineralys Therapeutics INC | Stock-Other | 3.32% | +0.85% | +112.28% | |
| 13 | ABVX | Abivax Sa-adr | Stock-Other | 2.39% | +0.28% | +61.08% | |
| 14 | GENB | Generate Biomedicines INC | Stock-Other | 2.03% | +2.03% | NEW | |
| 15 | PRCT | Procept Biorobotics CORP | Stock-Other | 1.79% | +1.79% | NEW | |
| 16 | GPCR | Structure Therapeutics INC | Stock-Other | 1.67% | +1.67% | NEW | |
| 17 | VRDN | Viridian Therapeutics INC | Stock-Other | 1.62% | -1.01% | +15.61% |
Performance for Q3 2026
+3%
Performance Last 4 Quarters
-2.1%
Based on 5 months of available history
Based on 70% of reported portfolio value with available pricing
Davern Capital Partners, LP's most significant position changes for 2026-03-31: New buy: Insmed INC (INSM); New buy: Generate Biomedicines INC (GENB); Sold out: Cg Oncology INC (CGON); New buy: Procept Biorobotics CORP (PRCT); New buy: Structure Therapeutics INC (GPCR).
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | LLY | Eli Lilly & Co | +4% | +228.39% | Add |
| 2 | NTRA | Natera INC | +2.1% | +83.05% | Add |
| 3 | IONS | Ionis Pharmaceuticals INC | +1.9% | +62.24% | Add |
| 4 | MLYS | Mineralys Therapeutics INC | +0.9% | +112.28% | Add |
| 5 | ABVX | Abivax Sa-adr | +0.3% | +61.08% | Add |
| 6 | ROIV | Roivant Sciences Ltd. | -0.6% | -15.06% | Trim |
| 7 | LEGN | Legend Biotech Corp-adr | -0.9% | +24.42% | Add |
| 8 | VRDN | Viridian Therapeutics INC | -1% | +15.61% | Add |
| 9 | ARGX | Argenx Se - Adr | -2.7% | -1.79% | Trim |
| 10 | REGN | Regeneron Pharmaceuticals | -3.6% | -14.54% | Trim |
| 11 | RPRX | Royalty Pharma plc | -3.7% | -38.14% | Trim |
| 12 | BNTX | Biontech Se-adr | -4% | -17.82% | Trim |
| 13 | PFE | Pfizer INC | -4.2% | -21.95% | Trim |
| 14 | INSM | Insmed INC | — | NEW | New buy |
| 15 | GENB | Generate Biomedicines INC | — | NEW | New buy |
| 16 | CGON | Cg Oncology INC | — | EXIT | Sold out |
| 17 | PRCT | Procept Biorobotics CORP | — | NEW | New buy |
| 18 | GPCR | Structure Therapeutics INC | — | NEW | New buy |
| Period | Filed | Type | EDGAR |
|---|---|---|---|
| 2026 Q1 | 2026-05-14 | 13F-HR | View on EDGAR |
| 2025 Q4 | 2026-02-13 | 13F-HR | View on EDGAR |
Institutions with a similar AUM
CIK 0001946237
Total reported value
$364.7M
87 stks
2026-03-31
AUM within 0.0% of this institution
CIK 0002011149
Total reported value
$364.3M
112 stks
2026-03-31
AUM within 0.1% of this institution
CIK 0001905962
Total reported value
$364.8M
111 stks
2026-03-31
AUM within 0.1% of this institution
Institutions with overlapping top holdings
CIK 0001086131
Total reported value
$41.1M
32 stks
2018-12-31
Stale — no recent filing
Also holds Pfizer INC as its largest position
CIK 0001590481
Total reported value
$32.0M
46 stks
2015-06-30
Stale — no recent filing
Also holds Pfizer INC as its largest position
CIK 0001694620
Total reported value
$8.3M
13 stks
2021-09-30
Stale — no recent filing
Also holds Pfizer INC as its largest position
Access Davern Capital Partners, LP's institutional profile programmatically:
REST API
curl https://alphasmo.com/api/v1/institutions/davern-capital-partners-lpCLI
npx alphasmo institutions get davern-capital-partners-lp